DEVELOPMENT OF AN INTERLEUKIN-11 SIGNALLING ANTAGONIST
Grant number: 1147621 | Funding period: 2018 - 2021
Interleukin (IL)-11 is a soluble signalling molecule that is associated with many types of cancer. We have recently discovered that IL-11 signalling is a novel and tractable therapeutic target for the treatment of colon cancer. The aims of this proposal are to understand the structural details of IL-11 signalling. We will use this information to develop new and improved therapeutics for colon cancer.